IL1B and myocardial infarction: Canakinumab, a monoclonal antibody (mAb) directed against interleukin-1β (IL-1β), significantly reduced adverse CV outcomes in patients with a history of myocardial infarction (MI) and elevated C-reactive protein (CRP) (4).